Neonc Technologies Holdings, Inc.
NTHI
$9.87
$0.798.70%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
10/1/2025
-
Globe Newswire
9/29/2025
-
Globe Newswire
9/22/2025
-
Globe Newswire
9/11/2025
-
TipRanks Financial Blog
9/10/2025
-
Globe Newswire
9/10/2025
-
Globe Newswire
8/25/2025
-
Globe Newswire
8/22/2025
-
TipRanks Financial Blog
8/19/2025
-
GuruFocus
8/19/2025
-
GuruFocus
8/19/2025
-
Globe Newswire
8/13/2025
-
TipRanks Financial Blog
8/11/2025
-
Globe Newswire
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
8/7/2025
-
Globe Newswire
8/4/2025
-
Globe Newswire
8/1/2025
-
TipRanks Financial Blog
7/30/2025
-
Globe Newswire
7/29/2025
-
Globe Newswire
7/28/2025
-
Globe Newswire
7/25/2025
-
TipRanks Financial Blog
7/23/2025
-
GuruFocus
7/23/2025
-
GuruFocus
7/23/2025
-
Globe Newswire
7/23/2025
-
Globe Newswire
7/22/2025
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Monday, August 18, 2025
Period Date
Monday, June 30, 2025
Next Filing
Beginning of January (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
310-663-7831
Address
23975 Park Sorrento
Calabasas, CA 91302
Calabasas, CA 91302
Country
Year Founded
Business Description
Sector
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a...
more